CN101068916A - 阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途 - Google Patents

阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途 Download PDF

Info

Publication number
CN101068916A
CN101068916A CNA2005800413696A CN200580041369A CN101068916A CN 101068916 A CN101068916 A CN 101068916A CN A2005800413696 A CNA2005800413696 A CN A2005800413696A CN 200580041369 A CN200580041369 A CN 200580041369A CN 101068916 A CN101068916 A CN 101068916A
Authority
CN
China
Prior art keywords
compound
alkyl
atazanavir
administered
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800413696A
Other languages
English (en)
Chinese (zh)
Inventor
K·卡萨亨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN101068916A publication Critical patent/CN101068916A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CNA2005800413696A 2004-12-03 2005-12-02 阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途 Pending CN101068916A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63294504P 2004-12-03 2004-12-03
US60/632,945 2004-12-03

Publications (1)

Publication Number Publication Date
CN101068916A true CN101068916A (zh) 2007-11-07

Family

ID=36565812

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800413696A Pending CN101068916A (zh) 2004-12-03 2005-12-02 阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途

Country Status (15)

Country Link
US (1) US20070259894A1 (cg-RX-API-DMAC7.html)
EP (1) EP1824957A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008521934A (cg-RX-API-DMAC7.html)
KR (1) KR20070085702A (cg-RX-API-DMAC7.html)
CN (1) CN101068916A (cg-RX-API-DMAC7.html)
AU (1) AU2005311672B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518741A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588466A1 (cg-RX-API-DMAC7.html)
IL (1) IL183383A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007006637A (cg-RX-API-DMAC7.html)
NO (1) NO20073403L (cg-RX-API-DMAC7.html)
NZ (1) NZ555215A (cg-RX-API-DMAC7.html)
RU (1) RU2403066C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006060731A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703989B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7491819B1 (en) 2004-05-28 2009-02-17 Bristol-Myers Squibb Company N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
RU2382648C2 (ru) 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
EP3165220B2 (en) 2004-12-03 2024-11-13 Merck Sharp & Dohme LLC Pharmaceutical composition containing an anti-nucleating agent
MX2009013565A (es) 2007-06-12 2010-06-02 Concert Pharmaceuticals Inc Derivados de azapeptidos.
US20100273203A1 (en) * 2009-04-23 2010-10-28 Board Of Trustees Of The University Of Arkansas Methods and compositions for detecting metabolites
US8410064B2 (en) * 2009-08-24 2013-04-02 The Board Of Trustees Of The University Of Arkansas Classical cannabinoid metabolites and methods of use thereof
WO2011026112A1 (en) * 2009-08-31 2011-03-03 The Board Of Trustees Of The University Of Arkansas Compositions comprising specific ugt inhibitors and methods of use thereof
AU2010313571B2 (en) 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor
US8883218B2 (en) 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
US9095598B2 (en) 2010-12-28 2015-08-04 The Board Of Trustees Of The University Of Arkansas Stilbenoid derivatives and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
EP1326865B1 (en) * 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
DE122009000048I1 (de) * 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
CA2463975A1 (en) * 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US20030215462A1 (en) * 2001-12-21 2003-11-20 Wacher Vincent J. Use of UGT inhibitors to increase bioavailability
WO2004058756A1 (en) * 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
US20040192624A1 (en) * 2003-03-24 2004-09-30 Kempf Dale J. Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
EP3165220B2 (en) * 2004-12-03 2024-11-13 Merck Sharp & Dohme LLC Pharmaceutical composition containing an anti-nucleating agent

Also Published As

Publication number Publication date
ZA200703989B (en) 2008-09-25
EP1824957A2 (en) 2007-08-29
BRPI0518741A2 (pt) 2008-12-02
EP1824957A4 (en) 2011-02-09
NO20073403L (no) 2007-08-31
RU2403066C2 (ru) 2010-11-10
WO2006060731A3 (en) 2006-09-28
NZ555215A (en) 2010-08-27
CA2588466A1 (en) 2006-06-08
US20070259894A1 (en) 2007-11-08
WO2006060731A2 (en) 2006-06-08
AU2005311672A1 (en) 2006-06-08
KR20070085702A (ko) 2007-08-27
AU2005311672B2 (en) 2010-07-22
MX2007006637A (es) 2007-06-19
RU2007125130A (ru) 2009-01-10
IL183383A0 (en) 2007-09-20
JP2008521934A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
CN1279040C (zh) 用于治疗的莨菪烷衍生物
CN101068793A (zh) Hiv整合酶抑制剂的钾盐
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN101031551A (zh) 针对癌症治疗的肝细胞生长因子/c-met活性的喹唑啉调节剂
CN1468217A (zh) 脂肪族含氮五员环化合物
CN1756547A (zh) 用作半胱氨酸天冬氨酸蛋白酶激活剂和细胞凋亡诱导物的3,5-二取代-[1,2,4]-噁二唑及类似物和其用途
CN1659148A (zh) 芳基肟化合物
CN1444582A (zh) 杂环化合物,它们的制备和用途
CN1630639A (zh) 新型吡啶-和喹啉-衍生物
CN1228087A (zh) 取代的嘧啶衍生物和它们的药物用途
CN1582277A (zh) 用作糖原合酶激酶3β抑制剂的酰胺衍生物
CN1433312A (zh) 作为治疗剂的巴比妥酸类似物
CN1269823C (zh) 作为抗心律不齐化合物的3,7-二氮杂双环[3.3.1]制剂
CN1856312A (zh) 治疗急性和/或慢性神经系统疾病的mGluR2拮抗剂和AChE抑制剂的组合产品
CN1788002A (zh) 作为钠通道阻滞剂的联芳基取代的三唑化合物
CN101068550A (zh) 含有释放速度控制组分的羧酰胺人类免疫缺陷整合酶抑制剂药物制剂
CN1655760A (zh) 速释药物制剂
CN101068533A (zh) 含有抗成核剂的药物组合物
CN1173951C (zh) 取代1,3-二芳基-2-吡啶-2-基-3-(吡啶-2-基氨基)-丙醇衍生物、其制备方法、含有它们的药物组合物及其应用
AU2005311672B2 (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1
CN1482118A (zh) 新颖的5-羟基-3-羧酸酯吲哚类衍生物及其制备方法
CN1875017A (zh) 取代的4-氨基-1-(吡啶基甲基)哌啶化合物的萘-1,5-二磺酸盐
CN1556698A (zh) 使用选择性iNOS抑制剂的神经保护治疗方法
CN1433427A (zh) 依匹乐酮晶型
CN1514839A (zh) 作为抗心律失常化合物的3,7-二氮杂双环[3.3.1]制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20071107